ARVN
Arvinas, Inc.
There isn't enough reported data to score ARVN yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ARVN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ARVN's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARVN PE Valuation
ARVN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ARVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ARVN's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ARVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.10 | +$0.71 |
| Q2 2026 | $0.24 | +$1.25 |
| Q1 2026 | -$3.18 | -$2.52 |
| Q4 2025 | -$1.14 | +$1.63 |
| Q3 2025 | -$0.81 | +$3.86 |
| Q2 2025 | -$1.01 | +$4.16 |
| Q1 2025 | -$0.66 | +$5.27 |
| Q4 2024 | -$2.77 | +$3.73 |
ARVN is still losing money, but far less than before: $0.10 per share over the past year, against $6.50 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ARVN on earnings quality, reporting a profit while its opponent remains loss making.
ARVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $500K | -99% |
| Q2 2026 | $249.7M | +1015% |
| Q1 2026 | $15.6M | -92% |
| Q4 2025 | $9.5M | -84% |
| Q3 2025 | $41.9M | -59% |
| Q2 2025 | $22.4M | -71% |
| Q1 2025 | $188.8M | +646% |
| Q3 2024 | $102.4M | +196% |
ARVN's revenue is shrinking: $500,000 last quarter, down 99% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11820% | -11716 points |
| Q2 2026 | 66% | +385 points |
| Q1 2026 | -409% | -447 points |
| Q4 2025 | -785% | -687 points |
| Q3 2025 | -105% | -46 points |
| Q2 2025 | -319% | -256 points |
| Q1 2025 | 38% | +367 points |
| Q4 2024 | -98% | N/A |
ARVN's operating margin was −11820% last quarter, down 11715 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ARVN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ARVN on profitability, with a higher operating margin.
ARVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.2M | +$49M |
| Q2 2026 | -$48.5M | +$48.1M |
| Q1 2026 | -$70.5M | +$18.8M |
| Q4 2025 | -$30.6M | +$53.8M |
| Q3 2025 | -$59.2M | +$69.5M |
| Q2 2025 | -$96.6M | -295% |
| Q1 2025 | -$89.3M | +$8.3M |
| Q4 2024 | -$84.4M | -$1.2M |
ARVN has burned cash in almost every quarter: −$160M over the past year, against −$330M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ARVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -300K shares |
| 1 year | -11% | -7.8M shares |
| 3 years | +21% | +11.3M shares |
| 5 years | +31% | +15.6M shares |
| Available history | +75% | +28.1M shares |
ARVN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $74.1M |
| Q4 2023 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ARVN Net Leverage
ARVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ARVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.8 | Neutral |
| Stochastic | 18.1 | Oversold |
ARVN's weekly RSI is 39 (neutral) and its Stochastic is 18 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ARVN PE vs Healthcare Sector
| Metric | ARVN | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 27% above |
ARVN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ARVN on valuation relative to its sector.
ARVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.26 | 5.4% below |
| 20 week MA | $8.06 | 15% below |
| 50 week MA | $9.82 | 30% below |
| 100 week MA | $10.2 | 33% below |
| 200 week MA | $19.7 | 65% below |
ARVN is in a downtrend: it's below all five of its weekly moving averages, and 65% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ARVN on trend strength, trading above more of its moving averages.
ARVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.8 | $82.2 | +97% |
| 2021 | $82.2 | $81.3 | -1.2% |
| 2022 | $81.3 | $32.7 | -60% |
| 2023 | $32.7 | $41.2 | +26% |
| 2024 | $41.2 | $19.0 | -54% |
| 2025 | $19.0 | $12.2 | -36% |
| 2026 YTD | $12.2 | $6.87 | -44% |
ARVN has finished lower in four of the last six years. It's down 44% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ARVN on returns for 2026, with the stronger performance.